Regience

[Renee]

Joachim, thanks for the kind words. I'm a firm believer there is research and trials currently going on that we don't know about, I try to dig and find out.

Regience has partnered with kotaro yoshimura. This guy has been researching a lot on hair loss. I have attached a study he did in 2010 using dermal papilla cells.
http://www.researchgate.net/publicat...e_regeneration

[lacazette]

That is great!! Riken center are probably the most Advanced in the organ regeneration knowledge and Tools. This regience company also made agreements for a collaboration with some Osaka and Tokyo universties high researchers that work on hair, and also with ROHTO Pharmaceutical to develop the clinical application based on in vitro and in vivo results

This company wants to be a leading company in regenerative medecine, and regarding hair, their multiple agreements will at least help the preclinical research to find that possible clinical application. They seems to gather all the knowledge/methods needed

"In August 2014, Regience made an agreement for collaboration research with Professor, Daisuke Tsuruta and visiting Professor, Katsutoshi Yoshizato in Department of Dermatology, Osaka City University Graduate School of Medicine, to develop regenerative medicine products for the treatment of alopecia and promotion of hair growth.
Professor, Daisuke Tsuruta and Lecturer, Kouji Sugawara are leading researchers in the dermatology field of hair growth, who developed cultivated human hair follicle model and animal hair cycle model
Regience starts the collaboration research to regenerate the hair cycle, consisting of growth, destruction and resting phases as intrinsic state and for this goal, the accumulating technologies Professor Tsuruta and Lecturer Sugawara established will be employed.


"Regience made an agreement with Tokyo University and ROHTO Pharmaceutical Co., Ltd. for collaboration research to the regeneration medicine of hair. Through this collaboration, Regience aims for the clinical application of regenerative medical products, developed upon the in vitro and in vivo studies with Koutaro Yoshimura,"

[lacazette]

"Innovative technologies including iPS cells are being created in Japan. We are aiming to utilize these technologies in the field of regenerative medical products and obtain the approval in foreign countries as well to sell these products. Besides, we are also aiming to develop one and only product in the world utilizing robotics and other manufacturing technologies"

the company president :
“Our purpose is to create innovative medicine in the field of regenerative medicine utilizing technologies originated in Japan and deliver it to the patients who need it all over the world as soon as possible.”

"Regenerative Medicine Industrialization Task Force (RMIT) has been established as a task force under Forum for Innovative Regenerative Medicine (FIRM). Japan has set up the most advanced legal and regulatory environment for industrialization of regenerative medicine and cell therapy since the progressive legislations that took place in the autumn of 2014. Encouraged by that, some of the FIRM member companies have volunteered to organize RMIT and organized an industrialization support team as its initiating activity. This support team is meant to help wide spectrum of organizations such as established mega pharmas, emerging venture businesses, or thriving academia, domestic and overseas alike, resolving various bottlenecks that hinder prompt industrialization of regenerative medicine and cell therapy."

[FooFighter]

Fantastic news for my mouse!

[JayM]

Fantastic news for my mouse!

Oh no I'm really sorry to hear that your mouse has lost it's hair

[lacazette]

"It was believed that bio-venture companies, especially who aim drug development, was typically high risk and high return for the investment.
However, now the situation will be changed in Japan, especially in the field of regeneration medicine. “Bills on Safety Assurance of Regenerative Medicine” and “Law for Partial Revision of the Pharmaceutical Affairs Law” will become effective at 25th November this year and they are to become strong driving forces to boost up the field of regenerative medicine. In this circumstance, the risk of the development of regeneration medical products will become drastically mitigated by obtaining seeds, whose clinical data are already filed in clinical researches performed in i.e., universities. Moreover, the regeneration medical products could be launched much earlier by utilizing the temporal approval system, compared with other conventional drugs. In this system, MHLW (Ministry of Health, Labour and Welfare) is able to temporally approve the regeneration medicine products whose clinical data represent safety and suggestive efficacy. After launching the products, further clinical trials will be continued to accumulate the efficacy and safety data for the authorization of the definitive approval. Furthermore, manufacturing of the regeneration medical products derived from human cells are definitively categorized in this new law and allowed to be outsourced as medical service. All together, bio-venture companies could minimize the risk of the development of the regeneration medical product and maximize the return by implementing several pipelines in low costs. Regience seeks to be the leading company in this field of regeneration medicine.

[Renee]

These guys have partnered with leading scientist in the field of hair regeneration who have researched androgenetic alopecia for at least 10-15 years. In a sense they are commercializing treatments/cure by these researchers. They are not starting research from scratch. If anything this puts pressure on other researchers to speed things up.

[lacazette]

"Regience K.K. (hereinafter, Regience) has reached an agreement of co-development with ANRITSU CORPORATION (hereinafter, ANRITSU) to begin the total management system development for regenerative medicine. In this agreement, we will develop a totally integrated management system for regenerative medicine with cell-based regenerative medical products and Personal Data Store (PDS) of the patient."


"Advance into Clinical stage
Novel manufacturing facility for clinical application is settled in Kobe Port Island
Regience K.K. (hereafter, Regience) settles the manufacturing facility in Kobe Port Island
(Kobe Biomedical Innovation Cluster), which enable us to manufacture the regenerative medical products in accordance with GMP régulations"

We are Lucky that japan take the turn a few years ago to become the leading regenerative medecine country. here the 5-10 years timeline for the available REAL CURE sounds to finally become a reality. Without them we would talk more about 15-30 lol ( except China who is the other leader with many clinical trials)

the temporally approval is a benediction, if Regience finalize a protocol during the next 2 years, we could in 2019/2020 see again in the mirror our lovely definitive framing faces haha that day will be unreal

We will have hair ! let's just hope we won't have to go then on the cancer forum section..lol

[nameless]

"Regience K.K. (hereinafter, Regience) has reached an agreement of co-development with ANRITSU CORPORATION (hereinafter, ANRITSU) to begin the total management system development for regenerative medicine. In this agreement, we will develop a totally integrated management system for regenerative medicine with cell-based regenerative medical products and Personal Data Store (PDS) of the patient."


"Advance into Clinical stage
Novel manufacturing facility for clinical application is settled in Kobe Port Island
Regience K.K. (hereafter, Regience) settles the manufacturing facility in Kobe Port Island
(Kobe Biomedical Innovation Cluster), which enable us to manufacture the regenerative medical products in accordance with GMP régulations"

We are Lucky that japan take the turn a few years ago to become the leading regenerative medecine country. here the 5-10 years timeline for the available REAL CURE sounds to finally become a reality. Without them we would talk more about 15-30 lol ( except China who is the other leader with many clinical trials)

the temporally approval is a benediction, if Regience finalize a protocol during the next 2 years, we could in 2019/2020 see again in the mirror our lovely definitive framing faces haha that day will be unreal

We will have hair ! let's just hope we won't have to go then on the cancer forum section..lol

The company that we want pressure put on is Samumed. And Shisheido is putting pressure on Samumed because Shisheido announced an iPS cell hair-loss treatment by 2018. This puts pressure on Samumed to market their SM04554 as fast as possible. I predict that SM04554 will enter the marketplace sometime between fall 2016 and late spring 2017.

[hellouser]

Fantastic news for my mouse!

LOL!!! So true. Anyone else sick of hearing about new mouse research?